Skip to content

Screener

Eligibility screening

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Sponsored by C. Babis AndreadisStudy detailsClinicalTrials.gov

1 US site in CA

Before we begin

Who are you filling this out for?

Your answer affects how the questions are phrased.